[The European Medicines Agency rejects the authorization of aducanumab for Alzheimer's disease]

Rev Neurol. 2022 Mar 16;74(6):207-208. doi: 10.33588/rn.7406.2022072.
[Article in Spanish]

Abstract

La Agencia Europea de Medicamentos rechaza la autorización del aducanumab para la enfermedad de Alzheimer.

Publication types

  • Letter

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Amyloid beta-Peptides
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Humans

Substances

  • Amyloid beta-Peptides
  • Antibodies, Monoclonal, Humanized
  • aducanumab